We develop novel network-based models to predict unknown adverse drug events and drug-drug interactions. Instead of waiting for sufficient post-marketing evidence to accumulate, this predictive approach can identify drug safety issues years in advance.
Banda JM, Callahan A, Winnenburg R, Strasberg HR, Cami A, Reis BY, Vilar S, Hripcsak G, Dumontier M, Shah NH. Feasibility of Prioritizing Drug-Drug-Event Associations Found in Electronic Health Records. Drug Saf. 2016 Jan;39(1):45-57.
Cami A, Reis BY. Concordance and predictive value of two adverse drug event data sets. BMC Med Inform Decis Mak. 2014 Aug 22;14:74.
Cami A, Manzi S, Arnold A, Reis BY. Pharmacointeraction network models predict unknown drug-drug interactions. PLoS One. 2013 Apr 19;8(4):e61468.
Cami A, Arnold A, Manzi S, Reis B. Predicting adverse drug events using pharmacological network models. Sci Transl Med. 2011 Dec 21;3(114):114ra127.
Reis BY, Olson KL, Tian L, Bohn RL, Brownstein JS, Park PJ, Cziraky MJ, Wilson MD, Mandl KD. A pharmacoepidemiological network model for drug safety surveillance: statins and rhabdomyolysis. Drug Saf. 2012 May 1;35(5):395-406.